FNA of New Thyroid Nodule
Yes, proceed with ultrasound-guided fine-needle aspiration (FNA) of the newly identified thyroid nodule in the right deep mid-lobe, and confirm whether the laboratory studies ordered on [DATE] have been completed.
Rationale for FNA
The presence of a new nodule that was not present on previous imaging is a critical finding that warrants investigation. According to the 2016 AACE/ACE/AME guidelines, the decision to perform FNA should be based on:
- Nodule size
- Ultrasound risk stratification (high, intermediate, or low risk features)
- Clinical context
Key Decision Points
For this new nodule, FNA is recommended if:
- The nodule is ≥10 mm with high US risk features (marked hypoechogenicity, irregular/microlobulated margins, microcalcifications, taller-than-wide shape) 1
- The nodule is >20 mm with intermediate US risk features (mildly hypoechoic without high-risk features) 1
- The nodule is >20 mm with low US risk features (isoechoic, spongiform, or predominantly cystic) AND is increasing in size 1
Additional factors favoring FNA regardless of size:
- Subcapsular or paratracheal location
- Suspicious lymph nodes or extrathyroid spread
- Personal or family history of thyroid cancer
- Coexistent suspicious clinical findings (e.g., dysphonia, rapid growth) 1
The 2022 French consensus (SFE-AFCE-SFMN) provides similar thresholds using EU-TIRADS scoring:
- EU-TIRADS 5 (high suspicion): FNA at >10 mm
- EU-TIRADS 4 (intermediate): FNA at >15 mm
- EU-TIRADS 3 (low suspicion): FNA at >20 mm 2
Why This New Nodule Requires Attention
The fact that this nodule is new and was not present on prior imaging is significant. While the guidelines don't specifically address "new" nodules differently from existing ones, the appearance of a new nodule warrants the same systematic evaluation as any thyroid nodule. The radiologist has already flagged it as "worthy of investigating," suggesting concerning features on ultrasound.
Technical Considerations for FNA
When performing the FNA:
- Use ultrasound guidance (mandatory for accuracy and safety) 1
- Aspirate at least 2 sites within the nodule to reduce false-negative results 1
- For multiple nodules, prioritize based on US findings (which has been done here—the new nodule is the priority) 1
- If the nodule has cystic components, sample solid or vascularized areas 1
Laboratory Studies Follow-Up
Regarding the laboratory studies ordered on [DATE]: You must verify completion of these labs, as they are essential for comprehensive thyroid nodule evaluation. The standard initial workup includes:
- TSH (most important initial test)
- Free T4 and Free T3 if TSH is low
- Thyroid peroxidase antibodies (TPOAb) if TSH is elevated
- Calcitonin only if medullary thyroid carcinoma is suspected based on FNA results or clinical history 1
If TSH is low or in the low-normal range with multiple nodules, thyroid scintigraphy may be indicated to identify functional autonomy, which would alter FNA recommendations (functional "hot" nodules generally don't require FNA unless they have suspicious ultrasound features) 1.
Common Pitfalls to Avoid
- Don't delay FNA based solely on nodule size if high-risk ultrasound features are present
- Don't biopsy more than 2 nodules in the same patient when selecting based on established criteria 1
- Don't skip ultrasound guidance—palpation-guided FNA is outdated and less accurate 1
- Don't assume benignity based on the stability of the other three nodules; each nodule must be evaluated independently
Next Steps After FNA
The cytology results will be classified into one of five diagnostic categories (nondiagnostic, benign, indeterminate, suspicious for malignancy, or malignant) 1. Management will then be tailored accordingly, with surgical referral for suspicious or malignant cytology, and surveillance for benign results with repeat FNA only if there are suspicious clinical/US findings or substantial growth (>50% volume increase) 1.